Search results
Showing 241 to 255 of 318 results for breast cancer
Breast reconstruction using lipomodelling after breast cancer treatment (IPG417)
Interventional procedures, IPG417 - Issued: January 2012 --> We have moved interventional procedures guidance 417 to become HealthTech guidance 280. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)
Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.
Artificial intelligence for analysing CT brain scans (MIB207)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing CT brain scans .
Endoscopic axillary lymph node retrieval for breast cancer (IPG147)
We have moved interventional procedures guidance 147 to become HealthTech guidance 93. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Early and locally advanced breast cancer: diagnosis and treatment (CG80)
This guideline has been updated and replaced by NICE guideline NG101.
Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)
This appraisal has been updated and replaced by NICE technology appraisal 214.
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
In development Reference number: GID-TA10592 Expected publication date: TBC
Evidence-based recommendations on tacrolimus (Protopic) and pimecrolimus (Elidel) for people with atopic eczema.
Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)
This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.
Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)
Interventional procedures, IPG296 - Issued: April 2009 --> We have moved interventional procedures guidance 296 to become HealthTech guidance 188. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Discontinued Reference number: GID-TA11411
Paclitaxel for the adjuvant treatment of early node-positive breast cancer (TA108)
This guideline has been updated and replaced by NICE guideline NG101.
Docetaxel for the adjuvant treatment of early node-positive breast cancer (TA109)
This guideline has been updated and replaced by NICE guideline NG101.
Faster, fairer access to HealthTech under new national programme
People across England and Wales are set to receive faster, fairer access to innovative HealthTech under the new National HealthTech Access Programme (NHAP).
Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)
This evidence summary has been updated and replaced by NICE guideline NG101.